biomed devic servic
price close busi februari
 smid-cap print notabl
tradeshow deck week med-tech
bottom line addit notabl smid-cap coverag print week name
inmd highlight advanc technolog treatment
diabet attd confer week madrid spain hope gain
insight broader competit setup across insulin pump cgm space
specif hope gain insight statu posit reimburs
momentum cgm europ updat on-going ap program grow
ecosystem connect devic softwar diabet manag
earn front alreadi seen upsid pre-announc artc
nonetheless look forward earn call expect gain
import new insight trend buy-rat stock lastli
make trip london snn result wrap earn
large-cap ortho space
earn page follow preview coverag name print result
week includ inmod inmd buy buy smith
nephew snn buy globu medic buy
recent trade trend med-tech
large-cap med-tech market cap trade wk/wk price-to-earnings
vs multipl last week group continu trade high end
multi-decad peak/trough level exclud depth financi crise
rel year respect
mid-cap med-tech market cap valuat also trade wk/wk end
week price-to-earnings multipl vs multipl last week mid-cap current
trade midpoint histor peak/trough rang
small-cap med-tech market cap trade flat wk/wk
ev/sal median multipl vs multipl last week group continu trade
midpoint multi-decad peak/trough rang respect
rel year note small-cap group achiev all-tim peak
multipl septemb prior peak peak
achiev multipl occas point med-tech group
multipl broke new high
canaccord genuiti global capit market group canaccord genuiti group inc cf tsx
recommend opinion express research report accur reflect research analyst person independ object
view compani secur subject report discuss herein
import inform pleas see import disclosur begin page document
earn week
inmod inmd buy tue bmo maintain posit
robust move share start year nearli ytd
sinc ipo august certainli shift near-term risk/reward
setup continu believ inmd differenti proprietari technolog
drive sustain market growth uniqu under-serv portion aesthet
market expect compani impress growth continu
inmd remain earli stage world-wide build-out new product
inmd thing look for/area focus
new product think inmd broad portfolio energi devic
current capabl serv entireti cosmet market
highlight recent/upcom product launch feel acceler
revenu growth specif evolv platform combin three
technolog bodi contour skin tighten electr muscl
stimul one hands-fre system hands-fre skin
tighten system avail us addit bodi contour
em serv strong competit sell point provid
physician effect system price one also offer
long-term cost save combin system reduc need
addit warranty/ servic contract inmod also sister system
evolv call evok hands-fre treatment face neck
product launch late januari look updat
earli demand call
world-wide roll-out inmod gain traction intern market
revenu almost y/i compani
distributor countri establish subsidiari australia
india last quarter drive direct revenu inmd direct oper
countri expect expans key territori continu
move forward specif china support ou revenu
acceler point us revenu percent total drop
y/i past quarter dynam expect continu
move forward look updat progress call
buy tue maintain posit
rocket ship ytd hit initi price target
alreadi come denot one five focu idea given
belief firm would deliv anoth year dd top-lin growth also
anticip inde seen ytd multipl expans investor got excit
myriad catalyst see horizon name converg data hr
may alreadi pre-announce beat earli januari cap strong
perform total revenu y/i
ahead our/consensu estim firm latest guidanc rang
look forward see momentum continu build driven
converge/mi burgeon pain manag franchis expand product
offer across appendag manag sphere mention firm
increas product posit ep gatekeep treatment
af relat arrhythmia believ firm initi guidanc
prudent conserv posit firm deliv upsid initi estim
estim revenu model expect appendag
manag stand-out perform y/i support hsd
growth open busi think converg mi
approval/launch latest acceler revenu growth
vs drive gm expans could come play end
beyond converg next big catalyst product
sentreheart acquisit think begin pay
expect fda approv domest launch lariat laac platform follow
dedic reimburs code late gener bullish
ep market think repres uniqu ep asset make firm
potenti target view given recent run stock howev
would keep gunpowd dri print work
head hr may tri triangul potenti converg outcom
good could take stock north time opinion
thing look for/area focus
outlook provid initi outlook
pre-announce result januari manag project revenu
rang adjust ebitda current
expect loss wed focus call
manag high-level outlook busi segment well
color around firm path profit acquisit
sentreheart atrc profit timelin push
favor sentreheart acquisit think investor will/should look
specif around atrc pathway profit
worth think adjust ebitda break-even fall
time-frame could push iron converg
eventu lariat launch hotter expect firm may see
opportun add aggress dedic sale support
team promot import platform
open busi outlook atrc open busi repres
firm matur franchis open opportun still remain highli
under-penetrated support potenti franchis growth
beyond applic open cardiac surgeri
us today receiv concomit treatment notwithstand tavr
expans histor savr market see franchis
deliv solid hsd growth least next year current
model growth support
level evidence/guidelin well pain manag contribut
launch new clamp also support adopt especi
cabg procedur accord check
opportun pain manag follow success initi launch
think atrc burgeon pain manag franchis could
continu expand via dedic rep addit upcom data
frost single-cent data set seem like nich opportun
think atrc move pain manag could becom materi
growth engin firm support strong macro tailwind opioid
crisi think investor focu franchis ramp
includ pace ad dedic resourc
posit print
smith nephew certainli interest ceo namal nawana
step pursu opportun late octob close
success stint ceo stock gap result
felt weak overst especi consid replac
roland diggelmann brought orthoped experi well establish view
compani given role board sinc earli forward
month stock complet recov actual
sinc ceo turnov net net despit recent run continu believ
share present attract risk/reward current level consensu
ep ev/sal believ snn comprehens view
differenti product portfolio support market share gain began
see momentum renew focu execut lead
upsid oper leverag ep growth look dynam
continu call
snn thing look for/area focus
recent acquisit smith nephew acquir osiri
give snn portfolio fast-grow regen medicin asset
includ two skin substitut product stravix grafix well
care product partner brainlab greatli enhanc digit
surgeri robot platform focu continu
recent acquisit tusker medic link privat med-tech compani
focu ent space specif in-offic solut
placement tympanostomi tube known ear tube net net
continu view recent acquisitions/partnership posit
provid core us orthoped wound care ent busi
differenti higher-growth asset look forward hear
addit detail call along plan addit
move
navio despit manag turnov activ expect
investor continu focu navio surgic system given
success commerci steal market share
mako encourag commentari robot launch
rosa last call manag continu speak highli
brainlab integr note excit around ad new hip softwar
onto next version navio give surgeon abil access
knee surgeri plan next gener robot platform
look forward hear detail around plan call
expect manag provid much detail regard
system placement look commentari regard physician
train util exist placement knee share gain driven
specif navio placement remind navio surgic system
compat compani journey ii genesi ii total
knee system beta launch
posit print
globu pre-announce result outperform top line specif
expect revenu y/i rel line
estim consensu growth driven
musculoskelet us segment howev pre-announce also includ
guidanc put revenu ep growth consensu guidanc
revenu ep cg/consensu
share gap result stay
past week paus unsurpris given gmed
return view manag commentari regard strong
underli demand us robust pipelin robot strong rep hire
provid evid weak guidanc simpli conservat keep mind
first guidanc new cfo keith pfeil signal chang
dynam net net continu believ underli spine opportun
see potenti breakthrough year emerg
diversifi ortho player drive meaning growth trauma total
joint capit equip robot imag top core spine
busi advis investor use recent weak buy opportun
thing look for/area focus
emerg robot imag given
increasingli competit market spinal robot mdt surgic synergi
strategi place unit implant util zbh pend launch rosa
expect follow shortli expect
investor attent squar focus toward deliv
y/i growth view market spinal robot
quickli becom crowd remain under-penetrated
total system place note expect launch imag
platform provid broad util across orthoped surgeri give
compel valu proposit hospitals/physician net net continu
view excelsiusgp innov compel robot
spine surgeri platform look updat futur expans plan
addit orthoped market call estim
place unit us ou expect see
addit unit place
beyond robot nass unveil
pre/intraop imag platform similar o-arm
provid multipl imag modal ct fluoroscopi digit rad
one-cart solut c-arm design manag kept commerci detail
close vest note would launch competit
current solut market indic price given
commerci success medtron surgic synergi strategi
util bundl purchas agreement capit system like
navig imag robot provid up-front cost return
guarante procedur util implant biolog view
unveil comprehens imag platform strong
competit play simpli put market estim current peg
player us market addit imag
platform provid product suit match market
leader someth expect use drive continu
share take effect posit compet top-down via
hospit contract bundl bottom-up tradit grassroot
ou growth call manag note especi robust growth
japan uk itali india austria expect growth
remain solid secur regulatori approv legaci
product launch key technolog acceler market like
japan current model growth ou see upsid
potenti high teen if/when emerg technolog scale
buy thur maintain posit
print
pre-announce impress result revenu
cg/consensu grow y/i result cap
impress saw share though note theyv taken
paus recent last sever week yet overtak
earli high per share clear sign regain
much investor trust lost choppi net net continu
view one attract name med-tech robust new product
flow stable/improv us spine market continu ou share take clear
lt margin expans road map suggest investor look past current lack
robot focu pipelin recent/upcom product launch note
robust seen sever year fill key portfolio gap
core us lumbar busi share still trade
consensu revs/ebitda/ep ahead expect acceler
commerci momentum suggest investor take anoth hard look
thing look for/area focus
puls puls unveil nass formal commerci
us alpha/beta trial on-going select ou market
remind puls modular natur mean physician select
compon want build upon iga procedur focu
began bring comprehens integr solut
eventu surgic automation/robot look futur
unveil robot modul nass slate
first-in-human use account regulatori
timelin suggest late clearanc broader launch
impress size smaller competit
maneuver robot arm note point
articul competit system enabl easier workflow
multipl approach option without re-posit patient alif
tlif xlif etc net net remain seen whether puls
near-term revenu driver model includ minim revenu
howev believ system key build infrastructur
capabl broaden util mi surgic techniqu someth
central growth core lumbar busi look
addit commentari call
robust line-up new product mani investor remain focus
puls surgic intellig system highlight broader
pipelin implant/ procedur product innov robust
seen sever year especi remind enabl
physician perform xlif alif surgic techniqu without re-
posit patient thu reduc procedur time cost
importantli addit alif compon allow
realiz increment case revenu mani case would
captur manufactur dilig suggest
potenti lead much increas per case revenu
nass highlight on-going launch despit
launch remain earli day support broad
physician educ program remind repeatedli call
driver growth expect hear updat
event week
market london scotland februari
kyle market london edinburgh tuesday februari
wednesday februari
jason mill market kansa citi home super bowl champion
chief wednesday februari
confer overview isc repres preemin confer focus
cerebrovascular diseas highlight session center acut
endovascular non-endovascular treatment acut neuroimag larg
arteri diseas clinic rehab recoveri among other
isc applic
advanc technolog treatment diabet attd madrid spain
confer matter attd one premier intern
diabet meet heavi focu devic technolog particularli
relev coverag
well hope learn specif hope gain insight
impact posit reimburs chang cgm europ data head
to-head use libr dexcom updat on-going ap program
well commerci feedback earli adopt senseon eversens
attd applic
confer overview crt lead intervent cardiolog confer
focus area coronari endovascular structur heart
confer target intervent cardiologist gener cardiologist
cardiothorac vascular surgeon structur intim forum
discuss cutting-edg data novel technolog evolv treatment
crt applic ew nvcn
buy mon sidelin
print
posit print
posit print
print
hold tue sidelin
print
buy tue buyer
hold wed bmo sidelin
print
seaspin buy wed buyer
posit print
print
posit print
print
mill market baltimor februari
jason mill market baltimore/washington wednesday
octob mean exclud high high- mean exclud high mean exclud high valuat mean exclud high decad high mean exclud high valuat mean exclud high histor valuationsltmp/eev/salesev/salesev/salesev/salesev/salesev/sal figur large-cap med-tech regress analysi
short-term trade tacticsful year strateg mindset valuat med-tech enter all-tim high favor stock elit and/or acceler growth and/or near-term upsid estim equal-weight recommend see balanc b/t bullish fundament larg tam strong sale growth gm trend high valuat med-tech group could see momentum growth vector aplenti space averag sale growth gm strong improv expect med-tech valuat remain elev growth sector stay robust top near-term trade idea ew expect rel robust med-tech ipo market next month name high-growth firm uniqu technolog address larg pricepric targetmkt cap p/eev/salesgmcurr growth vectors/larg tam vs peer upsid street om ep expect could re-rat higher upon reimburs resolut optimist long growth acceler next via mi converg laa incl sentreheart continu acceler growth us launch presbyopia launch eu new growth turnaround idea amp sale forc new product acceler growth/gm next year pricepric targetmkt cap p/eev/salesgmcurr ion china japan collect could upsid street watch q/q trend us proc growth/per procedur momentum portend upsid top/bottom line tougher comp watch tmtt tam still under-penetr new growth vector om leverag top-tier mngt team lt top bounceback next messi management comp base cf improv valuat huge runway growth upsid btk cad us repres compel growth like deceler still see trend-line stay buy pullback paradigm organ tx herculean task take time prime pricepric targetmkt cap p/eev/salesgmcurr bagger low trade signific premium comp intensifi competit expect valuat matur med-tech stori fewer growth call option exit tmvr mdd could augment pipelin current biz trend heavi plan invest limit near-term growth om valuat run alreadi om see much add leverag acquisit chang strategi profit/cf growth potenti earli tell bear pricepric targetmkt cap p/eev/salesgmcurr relev nich uniqu mis/robot technolog treat bph/prostat cancer take time scale tm tech best-in-class busi model need show trend toward improv margin lower compel technolog tiara tmvr reduc stent unstabl angina show promis need add capit current valuat mean exclud high cap larg mid cap peak/trough multipl forward price-to-earnings multipl small cap peak/trough multipl forward ev/sal valuat rich larg mid small-cap med-tech stock enter trade materi higher multipl base revenu ev/sal earn price-to-earnings point enter new calendar year past dozen year mean large-cap price-to-earnings multipl ex-outli higher decad ago year vs point y/i mean small-cap ev/sal ex-outli decad ago year vs higher y/i favor stock acceler growth near-term upsid estim coverag univers believ stock meet least one criterion ew continu prefer segment ew ideal vehicl play massiv tam tavr heart diseas intervenion coapt data augment add clinic evid new product approv acceler revenu growth tmvr beyond sever mvd preval avr expect repair replac technolog win mitral favor electrophysiolog a-fib one preval under-tr diseas ww reimburs ep procedur robust ep space think demonstr momentum/shar gain go forward peripher expect see combin stronger clinic evid increas reimburs level larger sale forc push uniqu technolog physician strong growth franchis pi boston scientif corporationmed devic sector februari compound-annual-growth-rate stock accumul pullback increas busi momentumtop idea recommend put new money work compound-annual-growth-rate surgic companyirhythm technolog inc atricur inc vapotherm inc med-tech valuat current histor compound-annual-growth-rate medic corpneovasc inc neuronet inc edward lifesci corporationintuit surgic inc penumbra inc cryolif inc qualiti compani current valuation/set-up balanc risk/rewardmerit medic system inc shockwav medic inc transmed group inc tactil system technolog inc micro-cap shot goal compound-annual-growth-rate vascular inc livanova plcnevro corp key narr coverag invest structuralp/eev/saleshistor peripher intervent figur med-tech dashboard kyle
short-term trade tacticsw expect reset stori reduc estim risk enabl upsid look tactic guidanc axgnw continu favor growth upsid beat-and-rais stori across med-tech snn pricepric targetmkt cap p/eev/salesgmcurr thoughtszimm met hold chain improv new product cadenc cultur chang taken hold stock still cheapglobu medic inc class year emerg diversifi ortho player robot becom crowd still upsid oppti utilizationsi-bon small-cap med-tech execut stori innov technolog larg best-in-class clinic data improv reimbursementalphatec hold complet new manag distribut strategi product share taker us spine new products/distributionseaspin hold product improv distribut clean balanc sheet compel valuat classic small-cap share take stori pricepric targetmkt cap p/eev/salesgmcurr thought best large-cap space dont fight neg sentiment pend acq ep growth oppti intact inmod ipo lock-up weigh share start fill treatment gap aesthet elit growth profitabilitysientra concern financ risk weigh greenshoot share take drive miradri uncertainti remainsmisonix growth stori undercov radar new product busi model drive momentumtela surpris investor contract win invest post-ipo drive growth stagnant pricepric targetmkt cap p/eev/salesgmcurr thoughtsdexcom support continu upsid lead conserv guid may provid buy opptysmith nephew plc sponsor portfolio support share gain see upsid estim need see execut valid multipl find better stori med-tech valuat reflect pharmaci launch chang game pt nuvas set differ stellar share perform reman share taker spine margin oppti alway loom intersect ent management ceo/cfo posit turnaround core execut sinuva slower gate lt oppti pricepric targetmkt cap p/eev/salesgmcurr thoughtsaxogen show stori oppti rebuild confid execut vs guidanc valuat compel conformi headwind persist need show execut new product launch commerci momentum pricepric targetmkt cap p/eev/salesgmcurr thoughtssenseon hold headwind cash burn patient access effort expect weigh share obalon therapeut transit year compani evolv retail medicin prove valu custom demandfebruari cap larg mid cap peak/trough multipl forward price-to-earnings multipl small cap peak/trough multipl forward ev/sal multiplesnam like investor sentiment make show-m stori compound-annual-growth-rate compound-annual-growth-rate posit discern chang fundament get compani current valuat may balanc risk/reward compound-annual-growth-rate compound-annual-growth-rate compound-annual-growth-rate buy-rat name compound-annual-growth-rate compound-annual-growth-rate compound-annual-growth-rate devic sector februari would put new money work compound-annual-growth-rate compound-annual-growth-rate remain rich rel basi look stock picker market favor qualiti growth think smid cap name approach cf focu investor space mean year mindsetexpect remain major theme long-term help support small-cap valuationsstay patient refin shop list favorit pullback buy list snn med-tech valuat current historichistor p/ekey narr coverag shift valu outpatientin environ increas cost/pric headwind hospit payer procedur normal reserv inpati set shift less acut set outpati whenev possibl due varieti factoror hospit payer procedur normal reserv tand improv medic technolog still minor specif patient gener younger healthier physician high-volum highly-skil provid hospit system vertic integr comprehens pre/post op capabier specif patient gener younger healthier physishift come yr intuit may revolution gener surgeri da vinci past emerg robot assist surgeri start take hold orthoped mako prove valu total joint competit hasda vinci past emerg roboov next year spine joint replac key focu player includ snn peopl live diabet us alon date improv comput power person technolog provid opportun empow diabet patient whose treatment requir constant analysi insulin dose carbohydr intak th date improv comput power perscomprehens view individu patient data lead better treatment prescript trend util decision-mak standpoint patient provid payer connectivity/analyt rise machin figur med-tech comp tabl larg cap
figur short interest januari top basi point chang short interest decemb januari bottom
